培美曲塞二钠、吉非替尼交替使用与序贯使用在EGFR突变型晚期老年肺腺癌的临床疗效观察

The clinical effect observation of the alternative and sequential application of pemetrexed disodium and gefitini in treating EGFR mutant advanced aged lung adenocarcinoma

目的:观察培美曲塞、吉非替尼交替使用与序贯使用在EGFR突变型晚期老年肺腺癌的临床疗效。方法:选取2013年10月—2015年1月我院收治的EGFR突变型晚期老年肺腺癌70例作为研究对象,随机分为观察组35例,对照组35例,对照组患者给予培美曲塞与吉非替尼交替使用治疗,观察组患者给予培美曲塞、吉非替尼序贯治疗,比较两组患者近期疗效、远期疗效及不良反应变化。结果:两组患者近期疗效比较,观察组部分缓解及稳定例数高于对照组,差异有统计学意义(P<0.05);两组患者PFS及OS远期疗效指标比较,差异无统计学意义(P>0.05);两组患者不良反应比较,差异无统计学意义(P>0.05)。结论:培美曲塞、吉非替尼交替使用与序贯使用治疗EGFR突变型晚期老年肺腺癌,近期疗效及远期疗效良好,临床应用安全性高。

Objective： To observe the clinical effect observation of the alternative and sequential application of pemetrexed disodium and gefitini in treating EGFR mutant advanced aged lung adenocarcinoma. Methods： 70 patients with EGFR mutant advanced aged lung adenocarcinoma, admitted to our hospital from October 2013 to January 2015, were randomized into the observation group and the control group evenly. The control group received alternative application of pemetrexed disodium and gefitini while the observation group received sequential application of pemetrexed disodium and gefitini, the short term effect, long term effect and the adverse reaction of two groups were compared. Results： As for the short term effect, the relieved and stabilized cases of the observation group excelled that of the control group, the difference was statistically significant（P〈0.05）; As for the long term effect, the difference of PFS and OS indexes in two groups was not statistically significant（P〈0.05）; As for the adverse reaction, the difference of two groups was not statistically significant（P〈0.05）. Conclusion： The alternative and sequential application of pemetrexed disodium and gefitini had both good short term effect and long term effect in addition to a high clinical security in treating EGFR mutant advanced aged lung adenocarcinoma.